Pasithea Therapeutics Corp. (KTTA) Dividend History

Company News

• Neurofibromatosis Type 1 Market Set to Witness Significant Growth During the Study Period (2020–2034) Driven by Advances in Treatment | DelveInsight

  The neurofibromatosis type 1 market is expected to grow significantly due to advances in treatment, increased diagnoses, and ongoing clinical trials. Unmet needs in adult populations and systemic disease management create opportunities for new entrants and differentiated strategies.

  GlobeNewswire Inc.

  Featured Companies: MRK SWTX
• Pasithea Therapeutics Announces Closing of $5 Million Public Offering

  Pasithea Therapeutics, a clinical-stage biotechnology company, announced the closing of a $5 million public offering to fund its ongoing research, clinical trials, and corporate initiatives.

  GlobeNewswire Inc.
• Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference

  Pasithea Therapeutics, a clinical-stage biotechnology company, announced that its Vice President of Business Development, Mathew Lazarus, will be presenting at the 2025 CAGLA NeauxCancer Conference in New Orleans. The presentation will provide an overview of Pasithea's next-generation macrocyclic MEK inhibitor, PAS-004, and the company's progress in clinical development.

  GlobeNewswire Inc.
• Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

  Pasithea Therapeutics, a clinical-stage biotechnology company, announced a $5 million private placement of its common stock and warrants. The company plans to use the proceeds for working capital and general corporate purposes.

  GlobeNewswire Inc.
• Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

  Pasithea Therapeutics announced the successful completion of long-term chronic toxicity studies for its lead candidate PAS-004, a next-generation macrocyclic MEK inhibitor. The studies in rats and dogs showed a consistent safety profile, supporting the potential of PAS-004 as a best-in-class MEK inhibitor.

  GlobeNewswire Inc.